New hope for inoperable liver cancer: targeted drug delivery shows promise
NCT ID NCT02028949
Summary
This early-stage study tested a new way to deliver chemotherapy directly to liver tumors in patients with inoperable liver cancer and cirrhosis. Researchers injected a drug called idarubicin mixed with an oily substance (lipiodol) into the artery feeding the liver, hoping it would target the cancer better with fewer side effects than standard treatments. The main goal was to find the safest dose and see how well patients tolerated this approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE NON-METASTATIC HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU de Dijon
Dijon, 21079 Cedex, France
Conditions
Explore the condition pages connected to this study.